68Ga-pentixafor PET/CT在超选择性肾上腺动脉栓塞术治疗醛固酮腺瘤中的应用价值
该前瞻性研究纳入25例临床诊断醛固酮腺瘤(APA)患者,在超选择性肾上腺动脉栓塞术(SAAE)前后行68Ga-pentixafor PET/CT和肾上腺静脉采血(AVS)。PET/CT与AVS定位患侧一致率达100%;治疗后有效者患侧SUVmax显著下降,无效者无变化,SUVmax下降幅度与PASO标准下的良好预后相关。
要点
- 25例APA患者中,AVS与68Ga-pentixafor PET/CT定位患侧的一致率达100%。
- SAAE术前患侧SUVmax为16.79±2.51,显著高于非患侧的4.56±0.57(P<0.01)。
- 治疗后有效者患侧SUVmax由16.75±2.54降至4.37±1.52(n=22,P<0.001)。
核心结论
- SUVmax下降与患者预后相关,68Ga-pentixafor CXCR4显像可用于APA患者SAAE术前和术后的评估。
研究设计与样本
- 前瞻性研究,纳入25例临床诊断的醛固酮腺瘤(APA)患者,所有患者均在SAAE前后接受68Ga-pentixafor PET/CT和肾上腺静脉采血(AVS)检查。
- SAAE术后按原发性醛固酮增多症手术结局(PASO)标准进行临床随访,监测药物类型、血压、血钾和醛固酮/肾素比值以评估手术效果。
主要发现
- 25例成功接受SAAE的APA患者中,男性14例,平均年龄51.88±8.89岁。
- AVS与68Ga-pentixafor PET/CT定位患侧的一致率达100%。
- 术前患侧SUVmax为16.79±2.51(n=25),显著高于非患侧的4.56±0.57(P<0.01)。
- 按PASO标准,25例中13例达到临床完全缓解,9例部分缓解,3例治疗无效;19例达到生化完全缓解,3例部分缓解。
- 治疗后22例达到完全或部分缓解,其患侧68Ga-pentixafor SUVmax显著下降(16.75±2.54 vs. 4.37±1.52,n=22,P<0.001);3例治疗无效者SUVmax无变化(17.07±2.72 vs. 16.17±2.72,n=3,P=0.842)。
关键数值与推荐
- 按PASO标准评估:25例中临床完全缓解13例、部分缓解9例、无效3例;生化完全缓解19例、部分缓解3例。
- 治疗后有效者(n=22)患侧SUVmax由16.75±2.54降至4.37±1.52(P<0.001);无效者(n=3)SUVmax由17.07±2.72变为16.17±2.72(P=0.842)。
- 以SUVmax下降≥65%和<65%分组,SUVmax下降与PASO标准下良好预后相关(P=0.009)。
临床怎么用
- 作者认为,68Ga-pentixafor CXCR4显像可用于APA患者SAAE术前和术后的评估。
- 作者认为,SUVmax下降与患者预后相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Expression of CXC chemokine receptor 4 (CXCR4) has proved to be a valuable tool for guiding the diagnosis and treatment of aldosterone-producing adenoma (APA). In this study, we evaluated whether CXCR4 imaging with 68Ga-pentixafor PET/CT shows significant changes after superselective adrenal artery embolization (SAAE). METHODS: We prospectively recruited 25 patients with clinically diagnosed APA. All patients were examined with 68Ga-pentixafor PET/CT and adrenal venous blood sampling (AVS) before and after SAAE. PET/CT showed that the tracer uptake of unilateral nodular adrenal gland was higher than that of normal adrenal tissue. AVS showed that the dominant secretory side was consistent with that on PET/CT. All patients were successfully treated with SAAE. Clinical follow-up was carried out according to primary aldosteronism surgical outcome (PASO) criteria, and included monitoring of drug type, blood pressure, serum potassium, and aldosterone/renin ratio to evaluate surgical effect. Post operation 68Ga-pentixafor PET/CT and the maximum standardized uptake value (SUVmax) were used to observe the uptake of adrenal lesions after SAAE. RESULTS: Among the 25 APA patients who successfully underwent SAAE, 14 were men and the average age was 51.88 ± 8.89 years. The consistency between AVS and 68Ga-pentixafor PET/CT reaches 100%. Before operation, the SUVmax of the diseased side (16.79 ± 2.51, n = 25) was significantly higher than that of the non-diseased side (4.56 ± 0.57, P < 0.01). According to PASO criteria, 13 of 25 patients achieved complete clinical remission, 9 achieved partial remission and the treatment was ineffective for three patients. 19 cases achieved biochemical complete remission and 3 cases achieved partial remission. Following the treatment, 22 patients showed complete or partial remission. The 68Ga-pentixafor SUVmax of the diseased side decreased significantly (16.75 ± 2.54 vs. 4.37 ± 1.52, n = 22, P < 0.001). For the patients who ineffective to the treatment, the SUVmax did not change (17.07 ± 2.72 vs. 16.17 ± 2.72, n = 3, P = 0.842). The 25 patients were divided into two groups according to the average value (≥ 65% and < 65%) of the decrease in SUVmax. The decrease in SUVmax correlated with a good patient prognosis under the PASO standard (P = 0.009). CONCLUSION: A decrease in SUVmax is related to the prognosis. CXCR4 imaging with 68Ga-pentixafor can be used for pre- and post-SAAE evaluation in patients with APA.
引用
- Zhoufei F, Qixiang Z, Wei Z, et al. The utility of 68Ga-pentixafor PET/CT in superselective adrenal artery embolization(SAAE) for treating aldosterone adenomas. Eur J Nucl Med Mol Imaging. 2025. PMID: 40815389. doi:10.1007/s00259-025-07465-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。